期刊文献+

自身免疫性甲亢131碘治疗后不同时期患者血清中TPO Ab水平的研究 被引量:2

Research on the level of serum TPO-Ab in patients with autoimmune hyperthyroidism after treatment of ^(131)I
下载PDF
导出
摘要 目的对自身免疫性甲亢病人进行131I治疗并进行随访,以探讨治疗后不同时期患者血清中TPO-Ab水平变化。方法 184例患者131I治疗后进行随访,并选择我院健康体检者为对照,观察治疗后1、3、6及12个月疗效和血清FT3、FT4、sTSH及TPO-Ab变化情况。结果随着131I治疗后时间延长,甲功正常者逐渐增多,治疗12个月后,甲功正常者101例(55.19%),甲减50例(27.62%),未治愈32例(17.49%),总治疗有效率82.51%,与治疗1、3、6个月有明显区别(χ2=9.158,P=0.000);治疗后FT3水平逐渐下降,但直到治疗12个月后,184例患者FT3平均水平仍高于正常对照,差异有统计学意义(P<0.05);FT4水平逐渐下降,在治疗3个月时仍高于对照(P<0.05),但在治疗6个月时与对照相比差异无统计学意义(P>0.05);治疗后sTSH水平逐渐升高,在治疗12个月后与正常对照差异无统计学意义(P>0.05);治疗1个月后TOP-Ab水平仍较高,且与其他时间段差异有统计学意义(P<0.05),治疗3个月、6个月和12个月TOP-Ab水平仍高于正常对照,但互相之间差异无统计学意义(P>0.05)。结论 131I治疗后FT4水平恢复较快,sTSH次之,FT3改善最慢,血清TPO-Ab水平有变化但变化不明显。 To explore the changes of serum TPO-Ab levels in autoimmune hyperthyroidism patients treated with 131I, total of 184 patients were treated with 131I and were followed up, with 32 healthy individuals as control, whose serum FT3, FT4, sTSH and TPO-Ab levels were detected and compared at 1 month, 3 months, 6 months and 12 months after the treatment. We found that along with the time after 131I treatment, more patients showed normal thyroid function: 12 months after the treatment, 101 patients demonstrated normal thyroid function (55.19%), while 50 cases showed hypothyroidism (27.62%) and 32 cases were not cured (17.49%), the total effective rate was 82.51%, which was statistically different with before (X2=9.158, P=0.000); FT3 level decreased gradually after treatment, but still higher than that of normal control (P〈 0.05); the level of FT4 decreased gradually from month 3 post treatment, and showed no significant difference with that of control group (P 〉 0.05) at month 6; sTSH level increased gradually after treatment, and reached the level of control at month 12 post treatment (P 〉 0.05); one month after treatment, the TPO-Ab level was still higher than that of control (/9〈 0.05), but at month 3, month 6 and month 12 post-treatment, the level of TPO-Ab showed no statistical difference with that of control (P〉 0.05). Take together, after 131I treatment, FT4 levels restore fast. then sTSH and FT3; TPO-Ab level changes but no obvious.
作者 谭庆玲
出处 《免疫学杂志》 CAS CSCD 北大核心 2013年第12期1057-1059,1063,共4页 Immunological Journal
关键词 自身免疫性甲亢 甲状腺过氧化物酶抗体131I Autoimmune hyperthyroidism Thyroid peroxidase antibody 131I
  • 相关文献

参考文献9

二级参考文献41

共引文献35

同被引文献14

  • 1Walter MA, Christ - Crain M, Eckard B, et al. Radioiodine thera- py in hyperthyroidism: inverse correlation of pre - therapeutic io- dine up take level and post - therapeutic outcome [J]. Eur J Clin Invest,2004,34 ( 5 ) :365 - 370.
  • 2Downs H, Meyer A, Flake D,et al. Clinical inquiries: How use- ful are autoantibodies in diagnosing thyroid disorders? [ J]. J Fam Pract ,2008,57 (9) :615 - 616.
  • 3Ross DS. Radioiodinc therapy for hyperthyroidism [J]. N Engl J Med,2011,364: 542 -550.
  • 4Hautzel H, Pisar E, Yazdan - Doust N, et al. Qualitative and quan- titative impact of protective glucoeorticoid therapy on the effective 1311 half - life in radioiodine therapy for Graves disease [ J ]. J Nu- cl Med,2010,51 (12) : 1917 - 1922.
  • 5Hamada N, Momotani N, Ishikawa N, et al. Persistent high TRAb values during pregnancy predict increased risk of neonatal hyper- thyroidism following radioiodine therapy for refractory hyperthyroid- ism [ J]. Endocr J,2011,58 ( 1 ) :55 - 58.
  • 6Kamath C, Adlan MA, Premawardhana LD, et al. The Role of Thy- rotrophin Receptor Antibody Assays in Graves' Disease [ J ]. J Thyroid Res,2012,23 (5) :52 - 56.
  • 7王超群,杨军,谢彦,杨继文,葛俊亮,程光华.甲亢患者^(131)Ⅰ治疗前血清TGAb和TPOAb含量与早发甲减关系的探讨[J].皖南医学院学报,2011,30(1):25-27. 被引量:3
  • 8伍宁玲,吕朝晖,杜锦,杨国庆,巴建明,窦京涛,母义明,陆菊明.促甲状腺激素受体抗体在Graves病中的诊断价值[J].解放军医学杂志,2011,36(5):501-504. 被引量:31
  • 9张新文,李三潭,姚志勇,林无生,李忠信.药物综合治疗对阵发性房颤患者左心房舒张期功能的影响[J].山东医药,2011,51(23):30-31. 被引量:1
  • 10蒋宁一,林岩松,关海霞,谭建,李林,高再荣,陆汉魁,吴艺捷,管樑,袁卫红,金刚,包建东,黄钢.^131I治疗格雷夫斯甲亢指南(2013版)[J].中华核医学与分子影像杂志,2013,33(2):83-94. 被引量:133

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部